A talk with Crinetics Chairman Scott Struthers, Ph.D.

During these trying times, work continues, even at a faster pace, for new drugs and therapies for pituitary patients.

From the J D Faccinetti, co-founder – We recently caught up with Crinetics Pharmaceuticals chairman Dr. Scott Struthers to discuss the latest on their new drugs currently under development. We wondered how this critically important work for pituitary patients was affected by the pandemic. Dr. Struthers gives us an “insider’s view” of their work and an update on the progress in the development of these new medications for acromegaly, neuroendocrine tumors, congenital hyperinsulinism, Cushing’s disease, congenital adrenal hyperplasia, and more. Don’t miss this fascinating discussion.

Click here to learn more about how you may be able to participate. For more in-depth information on this subject, listen to our podcasts series on new drug development, “The Journey to a New Drug.”


 

 

 

 

© 2020 – 2021, Pituitary World News. All rights reserved.

LEAVE A REPLY

Please enter your comment!
Please enter your name here